Advertisement

Targeted mesenchymal stem cell therapy for chronic obstructive pulmonary disease

      Chronic obstructive pulmonary disease is both an obstructive and inflammatory disease. Mesenchymal stem cell (MSC) therapy has shown early promise to modulate inflammation and improve lung function. The therapy has limitations resulting from cell loss and sub-optimal delivery. Our goal was to develop a MSC therapy that can use the inflammation in the lungs which results in SDF-1 expression as a target.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect